Literature DB >> 35113287

Predictors of hearing functional outcome following surgery for cerebellopontine angle meningioma.

Nida Fatima1, Anne K Maxwell2, Anna La Dine1, Zachary R Barnard1, Gautam U Mehta1, Eric P Wilkinson2, Derald E Brackmann2, William H Slattery2, Gregory P Lekovic3.   

Abstract

OBJECTIVE: Cerebellopontine angle (CPA) meningiomas can affect hearing function and require expeditious treatment to prevent permanent hearing loss. The authors sought to determine the factors associated with functional hearing outcome in CPA meningioma patients treated with surgery and/or radiation therapy in the form of either stereotactic radiosurgery or stereotactic radiation therapy.
METHODS: Consecutive patients with CPA meningiomas who had presented at our hospital from 2008 to 2018 were identified through retrospective chart review. Hearing function (as defined by pure tone average (PTA) and speech discrimination score (SDS) on Audiogram) was assessed before and after surgery for CPA meningioma. Audiograms with PTA > 50 dB and SDS < 69% were defined as poor hearing functional outcome. Multivariable Cox Proportional Hazards Regression Model was used to assess the associations between pre-operative hearing functional assessment and post-operative hearing functional outcomes.
RESULTS: The study cohort included 31 patients (80.6% females, with a mean age of 61.3 ± 15.2 years) with a median clinical follow-up of 5 months (range: 1 week-98 months). The mean pre-operative PTA and SDS were 23.8 ± 11.2 dB and 64.4 ± 22.2% respectively. At the last visit, there was significant hearing recovery, with an improvement of 29.7 ± 18.0 dB (p < 0.001) and 87.6 ± 17.8% (p < 0.001) in PTA and SDS respectively. After adjusting for age, gender, tumor volume, location, and tumor classification, Multivariable Cox Proportional Hazards Regression Model was conducted which revealed that patients undergoing surgery through retro sigmoid approach [Hazards Ratio (HR): 32.1, 95% Confidence Interval (CI): 2.11-491.0, p = 0.01] and gross total resection (GTR) (HR: 2.99, 95% CI: 1.09-9.32, p = 0.05) had significantly higher risk of poor hearing functional outcome compared to petrosal approach and near/subtotal resection. Moreover, patients with poor preoperative hearing had 85% higher chance of poor hearing functional outcome postoperatively (HR: 0.15, 95%CI: 0.03-0.59, p = 0.007).
CONCLUSION: Postoperative improvement in hearing is a reasonable expectation following surgery for CPA meningioma. Preoperative hearing, surgical approach and extent of surgical resection are predictive factors of postoperative hearing function outcome and can therefore aid in identification of patients at higher risk of hearing loss.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Cerebellopontine angle; Facial nerve; Hearing preservation; Hearing rehabilitation; Meningioma

Mesh:

Year:  2022        PMID: 35113287     DOI: 10.1007/s11060-022-03958-0

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  19 in total

1.  A new standardized format for reporting hearing outcome in clinical trials.

Authors:  Richard K Gurgel; Robert K Jackler; Robert A Dobie; Gerald R Popelka
Journal:  Otolaryngol Head Neck Surg       Date:  2012-08-29       Impact factor: 3.497

Review 2.  Posterior petrous bone meningiomas: surgical experience in 53 patients and literature review.

Authors:  Matthieu Peyre; Alexis Bozorg-Grayeli; Alain Rey; Olivier Sterkers; Michel Kalamarides
Journal:  Neurosurg Rev       Date:  2011-06-14       Impact factor: 3.042

3.  Accuracy and feasibility of estimated tumour volumetry in primary gastric gastrointestinal stromal tumours: validation using semiautomated technique in 127 patients.

Authors:  Sree Harsha Tirumani; Atul B Shinagare; Ailbhe C O'Neill; Mizuki Nishino; Michael H Rosenthal; Nikhil H Ramaiya
Journal:  Eur Radiol       Date:  2015-05-20       Impact factor: 5.315

4.  Meningiomas of the cerebellopontine angle with extension into the internal auditory canal.

Authors:  Florian Roser; Makoto Nakamura; Mehdi Dormiani; Cordula Matthies; Peter Vorkapic; Madjid Samii
Journal:  J Neurosurg       Date:  2005-01       Impact factor: 5.115

5.  Facial and cochlear nerve function after surgery of cerebellopontine angle meningiomas.

Authors:  Makoto Nakamura; Florian Roser; Mehdi Dormiani; Cordula Matthies; Peter Vorkapic; Madjid Samii
Journal:  Neurosurgery       Date:  2005-07       Impact factor: 4.654

Review 6.  [Anatomo-radiological classification of meningioma of the posterior skull base].

Authors:  M Desgeorges; O Sterkers
Journal:  Neurochirurgie       Date:  1994       Impact factor: 1.553

7.  Near complete surgical resection predicts a favorable outcome in pediatric patients with nonbrainstem, malignant gliomas: results from a single center in the magnetic resonance imaging era.

Authors:  Mary Kara Bucci; Amit Maity; Anna J Janss; Jean B Belasco; Michael J Fisher; Zelig A Tochner; Lucy Rorke; Leslie N Sutton; Peter C Phillips; Hui-Kuo G Shu
Journal:  Cancer       Date:  2004-08-15       Impact factor: 6.860

8.  Meningiomas of the cerebellopontine angle: radiological differences in tumors with internal auditory canal involvement and their influence on surgical outcome.

Authors:  Kun Gao; Housheng Ma; Yong Cui; Xuzhu Chen; Jun Ma; Jianping Dai
Journal:  PLoS One       Date:  2015-04-07       Impact factor: 3.240

9.  Nonvestibular Schwannoma Tumors in the Cerebellopontine Angle: A Single-Surgeon Experience.

Authors:  Vivek Kumar Kankane; Anshu Chandrakant Warade; Basant Kumar Misra
Journal:  Asian J Neurosurg       Date:  2019 Jan-Mar

10.  Hearing recovery after surgical resection of non-vestibular schwannoma cerebellopontine angle tumors.

Authors:  Naira Mkrtchyan; Lauranne Alciato; Michel Kalamarides; Daniele Bernardeschi; Olivier Sterkers; Isabelle Bernat; Mustapha Smail; Nadya Pyatigorskaya; Ghizlene Lahlou
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-06-27       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.